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CHAPTER I 
 
INTRODUCTION 
             
A month after the publication of their famous paper describing the structure of 
DNA, and a full 18 years before James Wang discovered the first topoisomerase, James 
Watson and Frances Crick published a second paper speculating on the implications of 
their discovery (1): 
“Since the two chains in our model are intertwined, it is 
essential for them to untwist if they are to separate. As they 
make one complete turn around each other in 34 A., there 
will be about 150 turns per million molecular weight, so 
that whatever the precise structure of the chromosome a 
considerable amount of uncoiling would be necessary. It is 
well known from microscopic observation that much 
coiling and uncoiling occurs during mitosis, and though 
this is on a much larger scale, it probably reflects similar 
processes on a molecular level. Although it is difficult at 
the moment to see how these processes occur without 
everything getting tangled, we do not feel that this 
objection will be insuperable.” 
 
Watson and Crick realized that the cell would require a mechanism to overcome the 
inevitable topological issues that would arise due to the inherent properties of their newly 
discovered DNA structure.  
 
DNA Topology 
In almost all living organisms, DNA is globally underwound (2-5). This property 
decreases the amount of energy needed to break the hydrogen bonds between the bases of 
DNA and therefore facilitates strand separation (5-8). Separation of the two strands of the 
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double helix must occur for transcription and replication to be carried out by RNA and 
DNA polymerases. 
 As the two strands of DNA are unwound by a polymerase-associated helicase, 
compensatory over- and under-winding occurs. Over-winding ahead of, and under-
winding behind, the replication or transcription machinery leads to positive and negative 
supercoiling, respectively (Figure 1) (9-12). Just as negative supercoiling facilitates 
normal DNA processes, positive supercoiling inhibits them. Because the ends of DNA 
are fixed in space (free rotation is hindered by DNA-associated proteins such as 
nucleosomes and membrane scaffolding, and bacterial DNA is circular), critical cellular 
processes such as replication and transcription would stall before completion without a 
mechanism to relieve the torsional stress (5,7,8,11). Furthermore, torsional stress ahead 
of DNA tracking systems is translated behind the fork and leads to the formation of 
precatenanes (Figure 1, bottom). Precatenanes link sister chromatids after replication and 
must be resolved in order for the chromosomes to be separated during mitosis (5,7,8,11). 
 The double helical nature of DNA is not the only topological challenge the 
genetic material presents to the cell. The human genome contains approximately 2 meters 
of DNA, which must be condensed into a nucleus roughly 5 microns in diameter (Figure 
2) (11,13). Although the circular genome of E. coli is about 1000 times smaller than that 
of the human genome, considerable packing must also occur. The sheer length of DNA, 
along with its compaction into a relatively small area leads to problems such as knots 
(recombination) and tangles (replication), as well as catenanes formed during daughter 
chromosome condensation and segregation (10,11,13).  
 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. Topological challenges to the cell arise due to the DNA tracking systems 
during replication and transcription. As the replication/transcription machinery (red) 
traverses the double helix, overwinding occurs ahead of the fork because the ends of 
DNA are fixed to membranes or protein scaffolding (gray boxes). This torsional stress 
can be translated into positive supercoiling ahead of the fork and/or precatenanes behind.  
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FIGURE 2. Approximately two meters of DNA must be condensed into nucleosomes and 
higher order structures in order to fit into the human nucleus, which is ~5 microns in 
diameter. This, along with the double-helical nature of DNA, would cause topological 
problems for the cell if not for topoisomerases. (From: Biochemistry (2nd Ed) C.K. 
Mathews & K.E. Van Holde. Benjamin/Cummings Publishing, Menlo Park, CA.)
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 The maintenance of proper DNA topology is controlled by a family of enzymes 
known as topoisomerases (11,13-17).   
  
Topoisomerases 
 Topoisomerases are essential to all known living organisms. Topoisomerases 
generally have three fundamental roles in cells: 1) Maintenance of appropriate 
chromosome topology, 2) removal of positive supercoils, and 3) unlinking of sister 
chromatids during replication, strand separation and cell division (11,13-17).  
Topoisomerases are classified by the number of DNA strands that they cleave during 
their catalytic reactions. Type I topoisomerases create a single, transient break in the 
DNA and type II topoisomerases cleave both strands. All topoisomerases cleave DNA by 
the nucleophilic attack on a phosphate of the phosphodiester DNA backbone by a 
catalytic tyrosine on the enzyme (Figure 3) (11,13-17). Due to the vital role of 
topoisomerases in the survival of the cell, they are important drug targets for anticancer 
and antibacterial therapeutics (18-25). 
  
Type I topoisomerases 
 There are two main subclasses of type I topoisomerases: type IA and type 1B 
(11,13,17,26). Type IA topoisomerases alter topology by cleaving one strand of DNA 
through the creation of a 5’ phosphotyrosine intermediate, passing the opposite strand 
through the break, and ligating the cleaved strand (11,13,17,26,27). They require a 
divalent metal ion but not ATP (reverse gyrase is the exception) (11,13,17,26,28).  
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FIGURE 3. During DNA cleavage mediated by type II topoisomerases, the active site 
tyrosine of the enzyme becomes covalently bound to the 5’-terminal phosphate at the 
scissile bond of the DNA backbone, generating a free 3’-hydroxyl group (for simplicity, 
only the reaction at one strand of the double helix is shown). In the reverse of the 
cleavage reaction, the DNA backbone is ligated through nucleophilic attack of the 
enzyme-linked phosphate by the –OH moiety. 
 
 7 
Because Type IA topoisomerases act on DNA that contains single-stranded character, 
they are unable to relax positive supercoils.  
 Type IB topoisomerases create a transient single-stranded break in the DNA 
through a 3’ phosphotyrosine covalent linkage (11,13,17,26). This leaves the 5’ end of 
the DNA free to rotate around the break before the DNA is resealed. This class of 
enzymes does not require ATP or a divalent metal ion. In contrast to type IA, type IB 
topoisomerases can relax both positive and negative supercoils as a result of their 
controlled rotation mechanism (11,13,17,26). 
 The human type IB topoisomerase, topoisomerase I, is a target for several 
anticancer drugs (26,29-32). Drugs such as camptothecin, topotecan, and irinotecan 
inhibit the enzyme from ligating the cleaved strand of DNA (13,30,31,33).  
 Because they cut only one of the two strands of the double helix, type I 
topoisomerases can only relieve supercoiling and are not able to resolve knots or 
catenanes (Figure 4). These topological forms require type II topoisomerases. 
 
Type II Topoisomerases 
 All living organisms encode at least one type II topoisomerase (13,17,34-37). This 
class of enzyme is able to relax (or in some cases induce) supercoils, untangle, and 
unknot DNA due to its ability to cleave both strands of the double helix (Figure 3). They 
are essential to cellular processes such as chromosome condensation, decondensation, 
and segregation (13,17,34-37).  
Type II topoisomerases act by passing one segment of DNA through a separate 
cleaved segment of DNA (18,22,37-45). To begin their catalytic cycles (see Figure 5),  
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FIGURE 4. Topoisomerases resolve various topological problems that arise due to various 
cellular processes. Overwinding of DNA occurs ahead of replication and transcription 
machinery. Type I and type II topoisomerases are able to relax DNA, thereby eliminating 
the torsional stress and allowing these cellular processes to continue. Because type I 
topoisomerases only cleave one strand of the double helix, they are unable to deal with 
structures such as knots and catenanes. These topological configurations result during 
recombination and replication and can only be resolved by type II topoisomerases.
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FIGURE 5. Type II topoisomerases (blue) preferably bind DNA at crossovers and, in the 
presence of a divalent cation, create a double strand break in one segment of the double 
helix (green). With the hydrolysis of an ATP molecule, the other segment of DNA 
(orange) is translocated through the break and the cleaved DNA is ligated. A second ATP 
molecule is hydrolyzed and the translocated segment is released and the enzyme can 
undergo another round of catalysis. 
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type II topoisomerases 1) bind two separate segments of DNA. 2) In the presence of 
divalent metal ions, the enzyme cleaves one of the segments (gate), creating a double-
stranded break. This is accomplished through the nucleophilic attack by two active site 
tyrosyl residues on the scissile phosphate of the DNA backbone. This results in a 5’-
phosphotyrosyl linkage on both strands of DNA, 4 bases apart from each other. The 
covalent enzyme-DNA intermediate is known as the “cleavage complex.” 
3) In the presence of ATP, the enzyme passes the intact segment of DNA 
(transport) through the double strand break. The type II topoisomerase then 4) religates 
the break in the gate segment. This is accomplished by the nucleophilic attack of the 
tyrosyl-bound 5’-phosphate by the free 3’-OH of the DNA backbone. Finally, 5) upon the 
hydrolysis of ATP, the enzyme releases the transport segment and 6) closes the protein 
gate. The type II topoisomerase can then either dissociate from the DNA or go through 
another round of catalysis. 
Type II topoisomerases act on the entire genome but it cleave DNA at preferred 
sites (46). Although general consensus sequences and DNA base preferences have been 
found, they are weak and there are many exceptions. It is not possible to use sequence 
information to consistently predict where type II topoisomerases will cleave DNA. It is 
therefore expected that the localized structure and properties of DNA such as flexibility 
have a great influence on topoisomerase II cleavage sites (47,48).  
 
Topoisomerase Poisons 
Type II topoisomerases are essential for the survival of proliferating cells but 
because their function requires the introduction of DNA double strand breaks, they also 
 11 
have the capability of fragmenting and destabilizing the genome (11,13,18,22). Levels of 
cleavage complexes must be maintained within a critical range. If levels drop too low, 
chromosomes will not properly separate during mitosis and the cell could die due to 
mitotic failure (Figure 6, left) (11,13,18,22). 
Cellular levels of cleavage complexes that are too high can also result in cell 
death. Helicases and polymerases associated with replication forks and transcription 
machinery can collide with these covalent topoisomerase II-DNA cleavage complexes 
(11,13,18,22,49). This causes the transient break to become permanent. The DNA breaks, 
as well as the error-prone products of recombination and repair, lead to mutations, 
deletions, and translocations. If the chromosomal damage is too great, programmed cell 
death pathways are triggered (Figure 6, right) (18,22,49-52). 
There are two classes of compounds that directly effect cellular concentrations of 
topoisomerase cleavage complexes (11,13,18,22). The first class, catalytic inhibitors, 
decrease the concentration of cleavage complexes by blocking normal enzyme activity 
(11,13,18,22). The second, topoisomerase poisons, increase levels of the covalent 
topoisomerase-DNA intermediate (11,13,18,22). These compounds turn the enzyme into 
a cellular toxin, triggering double strand breaks in the genome, as described above. 
Poisons of type II topoisomerases include environmental toxins, dietary compounds, 
anticancer, and antibiotic drugs (11,13,18,22). 
 
Bacterial Type II Topoisomerases 
Virtually every eubacteria encodes two type II topoisomerases; gyrase and 
topoisomerase IV (17,19,24,37,53,54). These enzymes help to regulate the superhelical  
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FIGURE 6. Type II topoisomerases are essential to all known living organisms. They carry 
out their necessary functions by the formation of covalent cleavage complexes. When the 
cellular concentration of these cleavage complexes becomes too low, such as in the 
presence of a catalytic inhibitor, proper control of DNA topology cannot be maintained 
and the cell can undergo slower growth, quiescence, mitotic failure, and even cell death. 
Conversely, when the concentration of cleavage complexes is too high, such as in the 
presence of a topoisomerase II poison, DNA strand breaks accumulate. DNA tracking 
systems such as helicases and polymerases can collide with the covalent topoisomerase-
DNA complex, resulting in permanent double strand breaks. These breaks can lead to 
recombination, chromosomal translocations, and cell death. 
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density of the bacterial chromosome and remove knots and tangles from the double helix. 
While gyrase and topoisomerase IV both alter DNA topology by generating transient 
double-stranded breaks in the genetic material and passing an intact segment of DNA 
through the break, the two enzymes to play different roles in the cell.  
Gyrase is a heterotetramer containing two subunits of GyrA and two of GyrB 
(GyrA2GyrB2) (13,17,19,24,37,53,54). Gyrase has a three-domain structure consisting of 
the ATPase domain, the DNA cleavage/ligation domain, and the C-terminal domain 
(Figure 7). GyrA containins the active site tyrosine and C-terminal domain, while GyrB 
is responsible for ATP binding and hydrolysis (13,17,19,24,37,53,54).  
Gyrase is the only known type II enzyme that is able to actively underwind the 
double helix (13,17,19,24,37,53,54). It is involved primarily in regulating the 
superhelical density of chromosomal DNA and alleviating torsional stress that 
accumulates ahead of DNA tracking systems. Generally, gyrase is more suited to deal 
with intramolecular DNA processes such as supercoiling. This is presumably due to the 
fact that it wraps DNA around itself, thereby bringing together two segments of the same 
localized section of the double helix (13,17,19,24,37,53,54). 
Topoisomerase IV shares the domain structure and ~40% sequence homology 
with gyrase. Like gyrase, it is a heterotetramer with two subunits of the DNA binding a 
cleavage domain (ParC) and two of the ATPase domain (ParE) (Figure 7) 
(13,17,19,24,37,53,54). Although it can relax positive and negative supercoils, 
topoisomerase IV does not wrap DNA and does not alleviate supercoiling nearly as well 
as gyrase (19,24,25,37,53-55). Topoisomerase IV, on the other hand, efficiently  
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FIGURE 7. Domain alignment of bacterial and human type II topoisomerases. E. coli 
gyrase and topoisomerase IV, along with human topoisomerase IIα and β are shown. The 
colors represent regions of homology. The N-terminal domain (purple)(GyrB and ParE in 
E. coli) is responsible for ATP binding and hydrolysis. The three vertical white lines 
represent conserved “Bergerat fold” motifs. The central homology domain (red) contains 
the active site tyrosine that forms the covalent bond with the DNA backbone. The C-
terminal domain (green) has the least sequence homology between species not closely 
related. In humans, this domain contains the nuclear localization sequence (NLS) and 
phosphorylation sites (PO4) 
 
 15 
decatenates DNA, and is the major enzyme that is responsible for unknotting and 
untangling the bacterial genome (19,24,25,37,53-55). 
   
Antibacterial Drugs 
Beyond their critical physiological functions, gyrase and topoisomerase IV are 
targets for quinolone-based antibacterial drugs (13,19,20,23,24). Members of this drug 
class, such as levofloxacin and ciprofloxacin, are among the most active and broad-
spectrum antibacterial agents currently in clinical use (Figure 8, right). Quinolones 
poisons cells by stabilizing covalent enzyme-cleaved DNA complexes, which are 
requisite intermediates in the DNA strand passage reactions of gyrase and topoisomerase 
IV (13,19,20,54,56-58). Cleavage complexes are converted to permanent strand breaks 
by collisions with helicases and other DNA tracking enzymes, triggering an SOS 
response in the bacterial cell (13,19,20,54,56-58).  
Gyrase and topoisomerase IV both contribute to the cytotoxicity of quinolones 
(19,20,59-61). However, the enzyme primarily responsible for cell death appears to be 
species- and drug-dependent. 
 
Human Type II Topoisomerases 
  
All eukaryotic type II enzymes are homodimeric and require ATP and divalent 
metal ions to perform their catalytic function (13,17). As seen in Figure 7, the eukaryotic 
type II topoisomerase retains the three-domain structure seen in the bacterial enzymes, 
although the domains are fused into one polypeptide. There is even a great deal of  
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FIGURE 8. Type II topoisomerase poisons. Left: Structures of clinically relevant 
chemotherapeutic drugs. Right: Examples of two anti-bacterial fluoroquinolones 
currently in clinical use.  
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sequence similarity between prokaryotic and eukaryotic excluding the C-terminus 
(13,17).  
The genomes of lower eukaryotes such as yeast and Drosophila encode only one 
type II topoisomerase (34,62-64). In contrast, vertebrates, including humans, encode two 
closely related isoforms of topoisomerase II, topoisomerase IIα and topoisomerase IIβ 
(11,17,36,37,65). The two isoforms have different molecular masses and are encoded by 
two separate genes (11,22,36,55,65-71). They display 70% amino acid sequence identity 
and share many enzymatic functions. The enzymes do, however, have different roles in 
the cell. The α isoform relaxes positive supercoils much faster than it does negative, but 
the β isoform does not discern the geometry of DNA supercoiling in vitro (72).  
 Topoisomerase IIα and β also differ in their expression patterns. Topoisomerase 
IIα is associated with replication forks and chromosomes during mitosis (16,73-76). 
Presumably due to its role removing tangles from DNA during replication and mitosis, 
the α isoform is essential for cell survival in proliferating cells. Its expression increases 
dramatically during periods of cellular growth (75,77-79). Expression of the α isoform is 
also regulated by the cell cycle, with levels peaking during G2/M (79-81).  
 In contrast to topoisomerase IIα, topoisomerase IIβ is not required for cell 
survival (65,66). It has, however, been shown to be necessary for neuronal development 
in mice (76,82). Expression levels of topoisomerase IIβ are cell cycle independent and do 
not increase within highly proliferating cells and it is not found on chromosomes during 
mitosis (66,76,83).  The β isoform cannot compensate for the loss of topoisomerase IIα 
(66,75,84,85). This suggests that, while the isoforms are very similar in structure and 
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mechanism, their physiological roles are quite different. Recent evidence suggests that it 
may be involved in the transcription regulation of developmental genes (84,86). 
   
Human Topoisomerase II poisons 
Many naturally occurring compounds in the human diet poison topoisomerase II. 
These include bioflavonoids, which are found in fruits and vegetables (87-96). One such 
bioflavonoid, genistein, a prominent compound in soy, is a potent topoisomerase II 
poison and is believed to have chemopreventative properties in adults (88-91,94,95). (-)-
epigallocatechin gallate (EGCG), a major component of green tea, also acts as a 
topoisomerase II poison (88,95,97). Environmental toxins such as quinones also poison 
the type II enzyme (98-106). 
Several topoisomerase II poisons are in wide clinical use as effective 
chemotherapeutic drugs. These include amsacrine, daunorubicin, doxorubicin, idarubicin, 
mitoxantrone, teniposide, and etoposide (Figure 8, left) (21,107-110). They are effective 
in the treatment of a number of malignancies including small cell lung and germ-line 
cancers, sarcomas, as well as leukemias and lymphomas (21,107-110). These drugs 
inhibit religation of the cleaved DNA strand in the topoisomerase II cleavage complex, 
leading to double strand breaks, which can lead to the generation of chromosomal 
aberrations, destabilize the genome, and trigger cell death pathways (21). 
  
Etoposide 
 Etoposide is a highly successful anticancer agent that has been used to treat a 
variety of blood-borne and solid human malignancies for nearly thirty years 
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(21,108,111,112). The drug is a derivative of podophyllotoxin, a naturally occurring folk 
remedy from mayapples that has been used for over a thousand years to treat various 
ailments (21,108). Podophyllotoxin blocks mitosis due to its ability to inhibit tubulin 
polymerization, but development as an anticancer drug was halted because of high 
toxicity (21,108). In the 1960’s two podophyllotoxin derivatives, teniposide and 
etoposide, were developed in the hopes of overcoming this toxicity (21,108). Two 
decades later, the FDA approved the drugs for cancer chemotherapy treatments. While 
these drugs of reduced toxicity were more effective antineoplastic agents, the mechanism 
of action was unknown. In the mid-1980’s researchers determined that topoisomerase II 
was the primary target of etoposide (21,108). 
 The individual contributions of topoisomerase α and β to the clinical efficacy of 
etoposide have yet to be determined. Etoposide has similar effects on levels of α- and β-
mediated DNA cleavage in vitro and targets both isoforms in cultured human cells, 
suggesting that both enzymes have a role in the cellular efficacy of the drug (21,108,113). 
However, recent evidence suggests that topoisomerase IIα may play a more prominent 
roll in mediating the cytotoxic effects of topoisomerase II-targeted anticancer drugs (114-
116). There is also evidence that topoisomerase IIβ is the isoform primarily responsible 
for off-site cardiotoxicity associated with topoisomerase II targeted chemotherapy (114-
116). Coupled with the fact that the concentration of topoisomerase IIα is generally 
higher in malignant as compared to corresponding normal tissues, most studies of 
etoposide action have focused on the α isoform (11,117-119). 
 Although etoposide has been an important chemotherapeutic drug during the last 
three decades, evidence suggests that its use also causes chromosomal translocations that 
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can lead to cancer formation (18,22,51,120-122). About 2-3% of patients treated with 
etoposide and other topoisomerase II-targeted regimens are eventually diagnosed with 
treatment-related leukemias (51,121). Most of these leukemias have translocations within 
a region of the mixed lineage leukemia (MLL) gene on chromosome 11 (51,121). The 
DNA breakpoints in the MLL gene and its translocation partner are typically near 
topoisomerase II cleavage sites.  
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Scope of the Dissertation 
 Type II topoisomerases are essential to all living organisms because of their roles 
in critical cellular processes such as replication, transcription, recombination, as well as 
chromosomal segregation, condensation, and decondensation (11,13-17). Type II 
topoisomerases also are important targets for anticancer and antibacterial drugs. These 
drugs use the catalytic activity of topoisomerase to create permanent double-stranded 
breaks in the genome, potentially leading to cell death (13,19,20,23,24,107-110). 
 Chapter I discusses DNA topology and bacterial and human topoisomerases, 
focusing on the type II enzyme. It includes an overview of the importance of these 
enzymes in the treatment of disease. 
 The materials and methods used in the research described in this dissertation are 
found in Chapter II. 
 Chapter III of this dissertation describes divalent metal ion usage in the bacterial 
topoisomerase IV cleavage reaction. It is demonstrated that DNA scission is enhanced 
when thiophilic metal ions are used with substrates that contain bridging sulfur atoms. 
This suggests that a metal ion is making a critical interaction with the 3’-bridging atom of 
the scissile phosphate of the DNA substrate. Furthermore, a series of experiments 
demonstrates that simultaneous binding of two metal ions is required for topoisomerase 
IV-mediated DNA cleavage. 
Chapter IV explores interactions between the D-ring and glycosidic moieties of 
the anticancer drug etoposide with human topoisomerase IIα. Previous experiments 
showed that these groups on etoposide do not interact with the enzyme in the binary 
protein-drug complex (138,139). Using a series of etoposide derivatives, it becomes clear 
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that the D-ring, and to a lesser extent, the glycosidic moiety, are important for drug 
activity. Changes in the D-ring also alter sites of enzyme-mediated DNA cleavage as well 
as decrease etoposide binding. These findings suggest that the D-ring of etoposide 
interacts with DNA in the topoisomerase IIα cleavage complex.  
Conclusions for the research described in this dissertation are summarized in 
Chapter V. 
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CHAPTER II 
 
METHODS 
 
Materials 
E. coli topoisomerase IV (1:1 ratio of ParC and ParE subunits) was expressed in 
E. coli and purified as described by Peng and Marians or by Corbett et al (123,124).. In 
the latter case, the cell pellet was resuspended in 20 mM HEPES (pH 7.5), 400 mM NaCl, 
10% glycerol and 2 mM β-mercaptoethanol, lysed by sonication and centrifuged. The 
supernatant was loaded onto a HisTrap HP column (GE Healthcare) and the protein was 
eluted with a linear gradient of 0–200 mM imidazole. The protein containing fractions 
were pooled and desalted on a HiPrep desalting column (GE Healthcare). The His-tag 
was removed by overnight incubation with AcTEV at 4°C using an OD280nm ratio 1:100 
AcTEV:protein, and the cleaved protein was filtered through a HisTrap HP column. The 
protein was concentrated and further purified on a Superdex 200 10/300 GL column (GE 
Healthcare). The concentrations of ParC and ParE were quantified by UV absorption. 
Human topoisomerase IIα was expressed in Saccharomyces cerevisiae and 
purified as previously described (125,126). However, in the final step of the purification, 
topoisomerase IIα was eluted from the phosphocellulose column (P81, Whatman) with 
buffer containing 10 mM sodium phosphate (pH 7.7), 750 mM KCl, 1 mM EDTA, 1 mM 
EGTA, and 0.5 mM dithiothreitol. For protein samples that were used in NMR 
experiments, the elution buffer was made up in D2O (99.9%, Aldrich) instead of H2O.  
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A 50-bp oligonucleotide duplex was designed using a previously identified 
topoisomerase II cleavage site from pBR322. This site corresponds to the sequence 
designated as site 2 by Fortune et al. (127). Wild-type oligonucleotide sequences were 
purchased from Sigma. The 50-mer top and bottom sequences were 5′-
TTGGTATCTGCGCTCTGCTGAAGCC↓AGTTACCTTCGGAAAAAGAGTTGGT-3′ 
and 5′-ACCAACTCTTTTTCCGAAGGT↓AACTGGCTTCAGCAGAGCGCAGATACC 
AA-3′, respectively (arrows denote sites of cleavage). 
DNA containing a single 3′-bridging phosphorothiolate linkage at the scissile 
bond (−1/+1 position) was synthesized as described previously (128). Substrates 
containing a racemic phosphorothioate in place of a non-bridging oxygen at the scissile 
bond or at the −2/−1 position of the bottom strand were synthesized by Operon. 
[γ-32P]ATP (∼5000 Ci/mmol) was obtained from PerkinElmer NEN. Single-
stranded oligonucleotides were labeled on their 5′-termini using T4 polynucleotide kinase 
(New England Biolabs). Following labeling and gel purification, complementary 
oligonucleotides were annealed by incubation at 70 °C for 10 min and cooling to 25 °C. 
Etoposide was purchased from Sigma. Retroetoposide, DEPT, retroDEPT, and the 
D-ring diol were synthesized as described previously (129). All drugs were stored at 4 °C 
as 20 mM stock solutions in 100% DMSO. Drugs used for NMR experiments were stored 
in 100% d-DMSO.  
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Procedures 
Topoisomerase IV-mediated cleavage of negatively supercoiled plasmid substrates 
DNA cleavage assays were carried out using the procedure of Fortune and 
Osheroff (130). Unless otherwise stated, assay mixtures contained 35 nM topoisomerase 
IV (1:1 ratio of ParC and ParE subunits) and 10 nM negatively supercoiled pBR322 DNA 
in a total of 20 µL of 40 mM Tris–HCl (pH 7.9), 2.5 mM MgCl2, MnCl2, or CaCl2 and 
2.5% glycerol. DNA cleavage mixtures were incubated for 10 min at 37 °C, and enzyme-
DNA cleavage intermediates were trapped by adding 2 µL of 5% SDS and 1 µL of 
375 mM EDTA (pH 8.0). Proteinase K was added (2 µL of a 0.8 mg/mL solution), and 
reaction mixtures were incubated for 30 min at 45 °C to digest the topoisomerase IV. 
Samples were mixed with 2 µL of 60% sucrose in 10 mM Tris–HCl (pH 7.9), 0.5% 
bromophenol blue and 0.5% xylene cyanol FF, heated for 2 min at 45 °C, and subjected 
to electrophoresis in 1% agarose gels in 40 mM Tris–acetate, (pH 8.3) and 2 mM EDTA 
containing 0.5 µg/mL ethidium bromide. DNA cleavage was monitored by the conversion 
of negatively supercoiled plasmid DNA to linear molecules. DNA bands were visualized 
by medium wavelength ultraviolet light and quantified using an Alpha Innotech digital 
imaging system. 
 
Topoisomerase IIα-mediated cleavage of negatively supercoiled plasmid substrates 
DNA cleavage reactions were carried out using the procedure of Fortune and 
Osheroff (130). Unless stated otherwise, assay mixtures contained 150 nM topoisomerase 
IIα and 10 nM negatively supercoiled pBR322 DNA in a total of 20 µL of topoisomerase 
IIα cleavage buffer [10 mM Tris-HCl (pH 7.9), 100 mM KCl, 5 mM MgCl2, 0.1 mM 
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NaEDTA, and 2.5% glycerol] that contained 0 to 200 µM etoposide, retroetoposide, 
DEPT, retroDEPT, or D-ring diol. DNA cleavage was initiated by the addition of enzyme 
and mixtures were incubated for 6 min at 37 °C to establish DNA cleavage-ligation 
equilibria. Samples were processed as above with the topoisomerase IV plasmid cleavage 
reactions.  
 
Topoisomerase IV-mediated cleavage of oligonucleotide substrates 
DNA cleavage assays were carried out by a modification of the procedure of 
Deweese et al. (130). Oligonucleotide substrates were always 5′-end-labeled. Unless 
otherwise stated, cleavage reactions contained 70 nM topoisomerase IV (1:1 ratio of ParC 
and ParE subunits) and 100 nM double-stranded oligonucleotide in a total of 10 µL of 
40 mM Tris–HCl (pH 7.9), 10 mM MgCl2, MnCl2 or CaCl2, and 2.5% glycerol. In some 
cases, the concentration of divalent cation was varied or combinations of the cations were 
used. Reactions were initiated by the addition of enzyme and were incubated for up to 
10 min at 37 °C. DNA cleavage products were trapped by the addition of 2 µL of 10% 
SDS. DNA products were precipitated in 100% ethanol, washed with 70% ethanol, dried 
and resuspended in 5 µL of sample loading buffer (40% formamide, 10 mM NaOH, 
0.02% xylene cyanol FF and 0.02% bromophenol blue). Cleavage products were resolved 
by electrophoresis in 14% denaturing polyacrylamide gels. To inhibit oxidation of 
cleaved oligonucleotides containing 3′-terminal –SH moieties and the formation of 
multimers in the gel, 100 mM DTT was added to the sample loading buffer (). DNA 
cleavage products were visualized and quantified using a Bio-Rad Molecular Imager. 
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Reversal of Topoisomerase IV cleavage complexes of oligonucleotide substrates 
 Assays were performed in the preceding section with the following changes: 
Either the cleavage reaction was terminated by the addition of SDS after 5 min or 2 µL of 
5 M NaCl was added to the cleavage reaction after 5 min and the solution was incubated 
for 5 min more before the addition of SDS. High salt conditions allow for ligation, but 
will not support DNA cleavage.  
 
Topoisomerase IIα-mediated cleavage of oligonucleotide substrates 
Assays were performed as above with topoisomerase IV with the following 
differences. A 47-bp oligonucleotide corresponding to residues 80−126 of pBR322 and 
its complement were employed to compare the DNA cleavage site specificity of 
etoposide to that of retroetoposide (131). Oligonucleotide substrates were purchased from 
Sigma. The sequences of the top and bottom strands were 5’-
CCGTGTATGAAATCTAACAATX↓CGCTCATCGTCATCCTC-GGCACCGT-3’ and 
5’-ACGGTGCCGAGGATGACGATG↓AGCGZATTGTTAGATTTCA-TACACGG-3’, 
respectively. This substrate contains a single strong cleavage site for topoisomerase II 
that has been well characterized (132-134). Arrows denote points of scission. 
Oligonucleotides were prepared that contained a G (found in the wild-type sequence), C, 
A, or T at the -1 position on the top strand (denoted by the bold X). Complementary 
bottom strand oligonucleotides contained a C, G, T, or A, respectively, at the position 
denoted by the bold Z. 
Reaction mixtures contained 220 nM human topoisomerase IIα and 100 nM 
double-stranded oligonucleotide in 20 µL of topoisomerase IIα cleavage buffer 
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containing 0–500 µM etoposide or retroetoposide. Reactions were incubated for 10 min 
at 37 °C.  
 
Topoisomerase IV-mediated cleavage of linear plasmid substrates 
 DNA cleavage sites were mapped using a modification of the procedure of 
O’Reilly and Kreuzer (135). A linear 4330 bp fragment (HindIII/EcoRI) of pBR322 
plasmid DNA singly labeled with 32P on the 5′-terminus of the HindIII site was used as 
the cleavage substrate. The plasmid was linearized by treatment with HindIII. Terminal 
5′-phosphates were removed by treatment with calf intestinal alkaline phosphatase and 
replaced with [32P]phosphate using T4 polynucleotide kinase and [γ-32P]ATP. The DNA 
was treated with EcoRI, and the 4330 bp singly end-labeled fragment was purified from 
the small EcoRI-HindIII fragment by passage through a CHROMA SPIN+TE-100 
column (Clontech). 
Reaction mixtures contained 1.4 nM labeled linear DNA and 35 nM 
topoisomerase IV (1:1 ratio of ParC and ParE subunits) in 50 µL of 40 mM Tris–HCl (pH 
7.9), 0–2.5 mM MgCl2, MnCl2 or CaCl2 and 2.5% glycerol. Reactions were initiated by 
the addition of enzyme and were incubated for 10 min at 37 °C. Cleavage intermediates 
were trapped by adding 5 µL of 5% SDS followed by 3 µL of 250 mM EDTA (pH 8.0). 
Topoisomerase IV was digested with proteinase K (5 µL of a 0.8 mg/mL solution) for 
30 min at 45 °C. DNA products were precipitated twice in 100% ethanol, washed in 70% 
ethanol, dried and resuspended in 5 µL of sample loading buffer. Samples were subjected 
to electrophoresis in 6% denaturing polyacrylamide gels. DNA cleavage products were 
visualized and quantified as above. 
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Topoisomerase IIα-mediated cleavage of linear plasmid substrates 
Assays were performed as above with topoisomerase IV with the following 
differences. Reaction mixtures contained 0.7 nM labeled pBR322 DNA and 90 nM 
human topoisomerase IIα in 20 µL of DNA cleavage buffer supplemented with 0.5 mM 
ATP in the absence of drug or in the presence of 10 µM etoposide, 25 µM DEPT, or 250 
µM retroetoposide, retroDEPT, or D-ring diol. Reaction mixtures were incubated for 6 
min. 
 
Drug-induced DNA cleavage mediated by topoisomerase IIα in cultured human CEM 
cells 
The In vivo Complex of Enzyme (ICE) bioassay (136,137) (as modified on the 
TopoGEN, Inc. website) was employed to determine the ability of 25 µM etoposide, 
retroetoposide, DEPT, retroDEPT, or D-ring diol to induce topoisomerase IIα-mediated 
DNA breaks in CEM cells. Human CEM acute lymphoblastic leukemia cells (ATCC) 
were cultured under 5% CO2 at 37 °C in RPMI 1640 medium (Cellgro by Mediatech, 
Inc.) containing 10% heat-inactivated fetal calf serum (Hyclone) and 2 mM glutamine 
(Cellgro by Mediatech, Inc.).  
Exponentially growing cultures were treated with DMSO or drugs for 1 h. Cells 
(~5 x 106) were harvested by centrifugation and lysed by the immediate addition of 3 mL 
of 1% sarkosyl. Following gentle dounce homogenization, cell lysates were layered onto 
a 2 mL cushion of CsCl (1.5 g/mL) and centrifuged in a Beckman NVT 90 rotor at 
80,000 rpm (~500,000  g) for 5.5 h at 20 °C. DNA pellets were isolated, resuspended in 5 
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mM Tris-HCl (pH 8.0), 0.5 mM EDTA, and blotted onto nitrocellulose membranes using 
a Schleicher and Schuell slot blot apparatus. Covalent cleavage complexes formed 
between topoisomerase IIα and chromosomal DNA were detected using a polyclonal 
antibody directed against human topoisomerase IIα (Kiamaya Biochemical Co.) at a 
1:1000 dilution. 
 
STD 1H NMR spectroscopy  
NMR spectra were generated using conditions similar to those described 
previously (138,139). All NMR experiments were performed at 283 K using a Bruker 
Avance 700 MHz spectrometer equipped with a 5 mm cryoprobe with z gradients. NMR 
buffers contained 10 mM sodium phosphate (pH 7.7), 250 mM KCl, 0.1 mM Na2EDTA, 
and 5 mM MgCl2. Samples (400 µL) contained 5 µM human topoisomerase IIα and 500 
µM etoposide, retroetoposide, DEPT, retroDEPT, or D-ring diol and were maintained at 
4 °C until data were collected. STD 1H NMR experiments employed a pulse scheme 
similar to that reported by Mayer and Meyer (140). A 2 s saturation pulse was used for 
the saturation, with on- and off-resonance irradiation frequencies of 0.5 and -71 ppm, 
respectively. The water signal was suppressed using excitation sculpting with gradients. 
For each experiment (on- and off-resonance irradiation), 256 scans were collected with a 
2 s recycle time. Difference spectra were prepared by subtracting the on-resonance 
spectrum from the off-resonance spectrum. Signals resulting in the difference spectrum 
represent the NOE difference signals generated by the transfer of irradiation energy from 
the enzyme to the bound ligand. Ligand protons in close spatial proximity with the 
enzyme displayed larger NOE signals. Mapping of the NOE signals with their proton 
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assignments on the ligand revealed the ligand-binding epitope to human topoisomerase 
IIα. Spectra were processed using Bruker Topspin software. 
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CHAPTER III 
 
USE OF DIVALENT METAL IONS IN THE DNA CLEAVAGE REACTION OF 
TOPOISOMERASE IV 
 
Introduction 
  As discussed in Chapter I, virtually every eubacteria encodes two type II 
topoisomerases, gyrase and topoisomerase IV (17,19,24,37,53,54). Gyrase is primarily 
involved in primarily in regulating the superhelical density of chromosomal DNA and 
alleviating torsional stress (17,19,24,37,53,54). Topoisomerase IV efficiently decatenates 
DNA, and is the major enzyme that is responsible for unknotting and untangling the 
bacterial genome. In addition to their critical physiological functions, both enzymes 
contribute to the cytotoxicity of the quinolone antibacterial drugs (17,19,24,37,53,54). 
 Despite the importance of gyrase and topoisomerase IV in the regulation of DNA 
topology in bacteria and the treatment of infectious diseases, many aspects of the DNA 
cleavage reaction are poorly understood. To this point, an area of emerging interest is the 
use of divalent metal ions in catalyzing the DNA scission event (141,142). 
 Based on the ability of mutant gyrase proteins to utilize metal ions, Noble and 
Maxwell (143) proposed that the bacterial enzyme utilizes a two-metal-ion 
phosphotransferase/hydrolase mechanism similar to that of DNA primases and 
polymerases (14,144).  In this mechanism, one divalent cation activates a catalytic water 
or ribose hydroxyl for nucleophilic attack, the other coordinates a leaving group, and both 
stabilize the pentavalent transition state. While the mutagenesis approach employed in 
this study provided evidence for the use of two divalent metal ions, it was not able to 
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provide information on the specific roles of the metal ions in the DNA cleavage/ligation 
reaction of gyrase. 
 A greater understanding of metal ion usage by type II topoisomerases was provided 
by enzymological and mutagenesis studies with human topoisomerase IIα and 
topoisomerase IIβ (142,145-149). These studies indicated that the human type II enzymes 
also employ a two-metal-ion mechanism. Furthermore, they suggested that one of the 
metal ions has an important interaction with the bridging oxygen of the scissile bond that 
greatly stimulates DNA cleavage. An interaction with the non-bridging oxygen of the 
scissile bond also was noted, but the ability of this interaction to stimulate DNA cleavage 
varied between the two human isoforms (142,145-149). 
 A recent crystal structure of the covalent yeast topoisomerase II-cleaved DNA 
complex contained both metal ions and led to the proposal that eukaryotic topoisomerase 
II employs a novel variation of the canonical two-metal-ion mechanism for DNA 
cleavage (Figure 9) (150). In this model, one metal ion (metal ion A) plays a direct role in 
the transition chemistry, most likely by promoting the leaving of the ribose 3’-OH. The 
other metal ion (metal ion B) appears to play a structural role in anchoring the DNA 
during cleavage.  
 Structures for non-covalent and covalent complexes formed between bacterial type II 
topoisomerases and DNA have been reported recently (151-154). In contrast to the work 
with yeast topoisomerase II, some of these structures contained divalent metal ions at site 
A or B, but none contained ions at both sites. These results led to an alternative proposal 
for the use of divalent cations by bacterial type II enzymes, suggesting that they use a 
“moving metal ion mechanism” in which only one of the two metal ion sites is filled at  
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FIGURE 9. Proposed two-metal-ion mechanism for DNA cleavage and ligation mediated 
by type II topoisomerases. A novel variant of the canonical two-metal-ion mechanism 
employed by primases and polymerases is shown. Amino acids in the active site that are 
postulated to function in catalysis by human topoisomerase IIα and topoisomerase IIβ, 
and by Saccharomyces cerevisiae topoisomerase II are indicated. The corresponding 
amino acids in the ParE and ParC subunits of E. coli topoisomerase IV are shown in 
italics. Metal ions (MA2+ and MB2+) are highlighted in red. Interactions between metal 
ions and nucleic acid and acidic amino acid residues are denoted in green and blue, 
respectively. In the proposed model, MA2+ makes critical contacts with the 3’-bridging 
atom (red) and a non-bridging atom of the scissile phosphate and plays a role in the 
transition chemistry and in stabilizing the leaving 3’-terminal oxygen. MB2+ contacts the 
non-bridging oxygen of the phosphate that connects the -1 and -2 bases upstream from 
the scissile bond and plays a structural role in anchoring the DNA during scission. Figure 
is adapted from Schmidt, et al. (150). 
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any given time (153-156).  
 In order to resolve this fundamental issue regarding the use of divalent metal ions 
by the bacterial type II enzymes, we carried out enzymological studies with E. coli 
topoisomerase IV. These studies utilized a series of divalent metal ions with varying 
thiophilicities in conjunction with DNA cleavage substrates that replaced specific 
bridging and non-bridging oxygen molecules with sulfur. Results strongly suggest that 
topoisomerase IV mediates DNA scission via a two-metal-ion mechanism and that one of 
the required divalent cations makes critical interactions with the bridging atom of the 
scissile bond during the cleavage event. Thus, it is proposed that the bacterial and 
eukaryotic type II topoisomerases utilize a common metal ion-dependent mechanism for 
cleaving DNA. 
 
Results and Discussion 
DNA cleavage mediated by E. coli topoisomerase IV is promoted by an interaction 
between a divalent metal ion and the bridging atom of the scissile phosphate 
 
E. coli topoisomerase IV, like other type II topoisomerases, requires a divalent 
metal ion to support DNA cleavage and overall catalytic activity (157). Although the 
physiological metal ion appears to be magnesium, the bacterial enzyme can utilize a 
variety of divalent cations for the DNA cleavage reaction in vitro (157,158). Figure 10 
shows the effects of metal ion concentration on topoisomerase IV-mediated DNA 
cleavage (left panel) as well as time courses for cleavage at constant metal ion 
concentrations (right panel). When negatively supercoiled plasmid was used as the 
substrate, Ca2+ supported the highest levels of DNA scission over a broad range of metal 
ion concentrations (left panel). Mg2+ and Mn2+ both supported DNA cleavage to a lesser  
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FIGURE 10. Cleavage of pBR322 plasmid by E. coli topoisomerase IV in the presence of 
different divalent metal ions.  The effects of cation concentration on DNA cleavage (10 
min reactions) are shown in the left panel. Mg2+ (green), Mn2+ (blue), or Ca2+ (red) were 
titrated from 0.1 to 10 mM.  Time courses for DNA cleavage in the presence of 2.5 mM 
divalent metal ions are shown in the right panel (Mg2+, green; Mn2+, blue; Ca2+, red). 
Time courses in the absence of metal ion (open squares) and at the optimal concentration 
for Mn2+ (0.35 mM Mn2+, yellow) also are shown. Error bars represent the standard 
deviation of three independent experiments. 
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extent (2– to 4–fold lower than Ca2+), but the optimal concentration of Mn2+ (~0.35 mM) 
was nearly an order of magnitude lower than that of Mg2+ (~2.5 mM). 
 Biochemical and structural studies with human and yeast type II topoisomerases 
suggest that active site metal ions in the eukaryotic enzyme interact with DNA at the 
bridging oxygen of the scissile bond (-1/+1 position), and non-bridging oxygen atoms at 
the scissile bond and the -2/-1 position (see Figure 9) (142,147-150). While the 
interactions at the scissile bond are believed to help mediate the chemistry of DNA 
cleavage, the interaction with the -2/-1 non-bridging oxygen is thought to play a 
structural role in the reaction (150). In order to characterize the role of the metal ion in 
the DNA cleavage reaction of topoisomerase IV, a series of oligonucleotide substrates 
was employed that substituted sulfur for the bridging (i.e., phosphorothiolate) or non-
bridging (i.e., phosphorothioate) oxygen atoms described above (Figure 11). 
 Wild-type oligonucleotides or substrates with substituted non-bridging atoms, 
establish rapid DNA cleavage-ligation equilibria. Treatment of these cleavage complexes 
with high salt allows for DNA ligation but not cleavage because dissociation occurs once 
the enzyme is no longer covalently bound to the DNA (Figure 12, left). In contrast, 
virtually no ligation of the phosphorothiolate substrate was observed following the 
addition of high salt to the topoisomerase IV-DNA cleavage complexes (Figure 12, 
middle/right). This is because the 3’-terminal –SH moiety that is generated following 
cleavage of the phosphorothiolate is a poor nucleophile for phosphorous (159,160). 
Metal ion-DNA interactions were determined by comparing the ability of 
topoisomerase IV to cleave substrates containing oxygen or sulfur atoms in the presence 
of metal ions of varying “hardness” (i.e., thiophilicity) (159,160). Experiments took 
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FIGURE 11. A phosphorothiolate substrate, with a sulfur replacing the 3’ bridging oxygen, 
is shown. The topoisomerase-mediated cleavage reaction proceeds just as with the wild-
type substrate. The active site tyrosine of the enzyme covalently binds to the 5’ 
phosphate, but in this case, a 3’-terminal –SH group is generated. This sulfhydryl group 
is a weak nucleophile and does not support ligation of the DNA. This allows for the study 
of cleavage in the absence of the possibly confounding ligation reaction.  
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FIGURE 12. Topoisomerase IV-mediated cleavage of a 50-mer oligonucleotide with a 3’-
bridging phosphorothiolate at the scissile bond is non-reversible. The central portion of 
the DNA cleavage substrate is depicted above the graphs. The asterisk denotes the 5’-
end-labeled strand and the scissile bonds are indicated by arrows. All modifications are 
on the bottom strand. The topoisomerase IV cleavage reaction of a wild-type 
oligonucleotide was terminated by SDS after 5 min (WT, blue bar). When NaCl, instead 
of SDS, was added to the cleavage reactions after 5 min, cleavage of the WT substrate 
was reversed (WT, red bar). When the same was done with the phosphorothiolate 
substrates, DNA cleavage was irreversible. The divalent cations used in these 
experiments were chosen for their ability to support high levels of topoisomerase IV-
mediated DNA cleavage. 
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advantage of the fact that “soft” metal ions such as Mn2+ (which are larger and more 
polarizable) often prefer sulfur over oxygen as an inner-sphere ligand, whereas “hard” 
metals such as Mg2+ and Ca2+ (which have a smaller ionic radius and are non-polarizable) 
usually coordinate more readily with oxygen (161-167). 
 Results with the wild-type oligonucleotide (Figure 13, left) were similar to those 
obtained with plasmid substrate. Once again, Ca2+ supported (by far) the highest levels of 
topoisomerase IV-mediated DNA cleavage. The only difference between results with the 
wild-type oligonucleotide and plasmid substrates was the fact that Mn2+ consistently 
supported higher levels of cleavage with the oligonucleotide than did Mg2+. 
 A substrate containing a 3’-bridging sulfur was employed to determine whether 
metal ion interactions with the bridging/leaving group facilitate catalysis. If this were the 
case, relative levels (or rates) of scission with substrates that contain a 3’-bridging 
phosphorothiolate should increase in the presence of soft metals and decrease in reactions 
that contain hard metals. 
 As seen in Figure 13 (right), metal ions produced a dramatically different 
cleavage pattern with the 3’-bridging phosphorothiolate as compared to the wild-type 
substrate. Cleavage rates were significantly higher and the levels of topoisomerase IV-
mediated DNA scission were nearly 10–fold higher with the sulfur-containing substrate 
in the presence of the soft metal Mn2+. Conversely, the hard metal Ca2+, which supported 
the highest levels of cleavage with the wild-type substrate, generated the slowest rates of 
cleavage and the lowest levels of scission with the sulfur-containing oligonucleotide. 
Despite the fact that cleavage complexes accumulate over time with the 3’-bridging 
phosphorothiolate, levels of cleavage seen with Ca2+ fell more than 10–fold as compared  
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FIGURE 13. Cleavage of oligonucleotide substrates by topoisomerase IV in the presence 
of different divalent metal ions. The central portion of the DNA cleavage substrate is 
depicted above the graphs. The asterisk denotes the 5’-end-labeled strand and the scissile 
bonds are indicated by arrows. All modifications are on the bottom strand. Results for the 
wild-type oligonucleotide (WT, left), and substrates containing a 3’-bridging 
phosphorothiolate at the scissile (-1/+1) bond (SPO, right) are shown. DNA cleavage was 
carried out in the presence of 10 mM Mg2+ (green), Mn2+ (blue), or Ca2+ (red). Error bars 
represent the standard deviation of three independent experiments. 
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to wild-type reactions. The precipitous drop in Ca2+-supported scission of the sulfur-
containing substrate, coupled with the increased scission observed with Mn2+, 
demonstrates that there is an important interaction between the metal ion and the 3’-
bridging atom of the scissile bond in the active site of E. coli topoisomerase IV that 
promotes the DNA cleavage event. Similar conclusions have been drawn for human 
topoisomerase IIα and topoisomerase IIβ (147,148). 
 
Divalent metal ion interactions with non-bridging phosphate atoms 
Interactions between metal ion A and the non-bridging oxygen atom of the 
scissile phosphate have been observed in the crystal structure of the covalent yeast 
topoisomerase II-cleaved DNA complex (150). While similar interactions in the active 
site of human topoisomerase IIα and topoisomerase IIβ have been proposed on the basis 
of kinetic experiments, their importance in the DNA cleavage reaction of these enzymes 
differs considerably (142,147,148). The relative ability of topoisomerase IIα to utilize 
different divalent metal ions with substrates that contain a racemic phosphorothioate at 
the non-bridging position of the scissile phosphate (-1/+1) was similar to that observed 
with the wild-type substrate (148). In contrast, the interaction between the metal ion and 
the non-bridging oxygen appears to play a more substantial role in the DNA scission 
reaction of topoisomerase IIβ (147). The relative ability of Ca2+ to support cleavage of 
the racemic non-bridging phosphorothioate decreased and fell below that of Mg2+ (147). 
 Given these differences, we wanted to determine whether the use of metal ions by 
topoisomerase IV was more similar to that of topoisomerase IIα or topoisomerase IIβ. 
Therefore, we examined the ability of different metal ions to support topoisomerase IV-
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mediated cleavage of the non-bridging phosphorothioate (-1/+1) substrate. As seen in 
Figure 14 (left), the relative use of metal ions approximated that seen with the wild-type 
substrate. Once again, the order of metal ion utilization was Ca2+> Mn2+> Mg2+. On the 
basis of these data, E. coli topoisomerase IV appears to utilize metal ion A (at least with 
respect to interactions at the non-bridging oxygen of the scissile phosphate) in a manner 
similar to that of human topoisomerase IIα. 
 As discussed above, the crystal structure of the covalent yeast topoisomerase II-
DNA cleavage complex revealed a novel interaction between metal ion B and the non-
bridging oxygen of the phosphate at the -2/-1 position (150). It is believed that this 
contact plays a structural role in anchoring the double helix during the cleavage/ligation 
reaction. Therefore, the effects of this interaction on rates of DNA cleavage were 
determined. Once again, the use of metal ions was similar to those seen with the wild-
type substrate (Figure 14, right). These findings cannot rule out an interaction between 
metal ion A or B and the -2/-1 non-bridging oxygen atoms. However, if these interactions 
exist in the active site of topoisomerase IV, their effects on the overall rate of DNA 
cleavage appear to be equivocal. 
 
A two-metal-ion mechanism for DNA cleavage mediated by topoisomerase IV 
Biochemical, kinetic, and mutagenesis studies with human topoisomerase IIα and 
topoisomerase IIβ indicate that both DNA cleavage/ligation active sites contain two 
divalent metal ions (145-149). Furthermore, the eukaryotic enzymes cleave DNA using a 
two-metal-ion mechanism in which metal ion site A and site B must both be occupied 
(142,147-149).  This model for eukaryotic topoisomerase II is strongly supported by a  
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FIGURE 14. Cleavage of oligonucleotide substrates by topoisomerase IV in the presence 
of different divalent metal ions. The central portion of the DNA cleavage substrate is 
depicted above the graphs. The asterisk denotes the 5’-end-labeled strand and the scissile 
bonds are indicated by arrows. All modifications are on the bottom strand. Results for the 
non-bridging phosphorothioate at the scissile bond (-1/+1 NB, left), and a non-bridging 
phosphorothioate at the -2/-1 position (-2/-1 NB, right) are shown. DNA cleavage was 
carried out in the presence of 10 mM Mg2+ (green), Mn2+ (blue), or Ca2+ (red). Error bars 
represent the standard deviation of three independent experiments. 
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recent structural study of the covalent yeast topoisomerase II-cleaved DNA complex 
(150). In this structure, both metal ion sites on each enzyme protomer are filled 
simultaneously. 
 Noble and Maxwell found that mutant gyrase proteins with substitutions at 
residues believed to complex with metal ions displayed greater DNA cleavage in the 
presence of Mg2+ and Ca2+ than did either divalent cation alone (143). Based on these 
findings, they proposed that the prokaryotic type II enzyme utilized a two-metal-ion 
mechanism. 
 This conclusion was challenged by a recent crystallographic study that examined 
non-covalent complexes between Staphylococcus aureus gyrase, DNA, and inhibitors 
(153). Although structures were generated that contained a metal ion at site A or B, none 
were observed that included metal ions at both sites. Based on these findings with gyrase, 
the authors proposed that type II topoisomerases utilize a moving metal ion mechanism in 
which only one of the two metal ion sites in each protomer is filled at any given time 
(153,155,156). In this model, metal ion binding to site B promotes DNA binding, albeit 
in a conformation that does not support efficient DNA cleavage. Once this conformation 
has been achieved, the first metal ion dissociates and is replaced by a second metal ion 
bound to site A, which promotes efficient DNA cleavage. 
 Recently, two structures of the covalent Streptococcus pneumoniae topoisomerase 
IV-cleaved DNA complex were reported. One of the structures contained no metal ions 
(151), while the other contained a single Mg2 (consistent with metal ion A) at each active 
site (154). Although the authors “[could not] exclude the participation of a more weakly 
 46 
bound Mg2+,” they also suggested the possibility that topoisomerase IV might utilize a 
single dynamic metal ion for DNA cleavage (154). 
 An important issue should be noted regarding the proposed moving (or dynamic) 
metal ion mechanism: the affinity of metal ion B, which would be the first to bind the 
enzyme in this model, is ~10–fold lower than that of metal ion A, which is the cation that 
participates directly in the chemistry of the cleavage reaction (147-149). 
 Two independent approaches were used to determine whether bacterial type II 
topoisomerases utilize a two-metal-ion or a moving metal ion mechanism for DNA 
cleavage. In the first, the concentration dependence of divalent metal ions for DNA 
cleavage mediated by E. coli topoisomerase IV was assessed. Initial studies utilized end-
labeled linear pBR322 as the cleavage substrate. Several striking features were seen 
(Figure 15). The most obvious is that no DNA scission was observed at low 
concentrations of Mg2+, Mn2+, or Ca2+. For each of the three metal ions, cleavage 
products were generated only after a threshold concentration had been reached (~0.05-
0.25 mM, depending on the metal ion), and began to accumulate coordinately for all 
observable DNA bands. Furthermore, when quantified, the metal ion dependence of DNA 
cleavage appeared to be sigmoidal in shape (Figure 16). 
 These data strongly suggest that each enzyme protomer contains two distinct sites 
for metal ion binding in the topoisomerase IV-DNA complex, and that both are critical 
for cleavage of each strand of the double helix. One metal ion binds to the complex with 
higher affinity (metal ion A) and saturates the site at levels that reflect the threshold 
concentration at which cleavage appears. The second (metal ion B) also is essential for 
DNA cleavage and associates with the topoisomerase IV-DNA complex with apparent 
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FIGURE 15. Metal ion concentration dependence for topoisomerase IV-mediated DNA 
cleavage of linearized pBR322 plasmid. A 4330 bp fragment of pBR322 was singly end-
labeled and employed as the cleavage substrate. Reaction products were resolved by 
acrylamide gel electrophoresis. DNA cleavage in the presence of varying concentrations 
of Mg2+, Mn2+, or Ca2+ (left, center, or right, respectively) is shown. The gel is 
representative of three independent experiments. 
 
 
 
 48 
0.5 1.00
0
20
40
60
80
100
[Ca2+] mM
0 1 2
0
5
10
15
20
25
[Mg2+] mM
0.1 0.20
0
5
10
15
20
25
[Mn2+] mM
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 16. Metal ion concentration dependence for topoisomerase IV-mediated DNA 
cleavage of linearized pBR322 plasmid. Data from Figure 15 and additional experiments 
were quantified. Results for Mg2+(top left), Mn2+(top right), and Ca2+ (bottom) are shown. 
All values were quantified relative to the most abundant cleavage product (generated at 
0.75 mM Ca2+), which was set to 100. Error bars represent the standard deviation of three 
independent experiments. 
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KD values of ~1.0, 0.12, and 0.40 mM, respectively for Mg2+, Mn2+, and Ca2. It is not 
obvious how the concentration dependence of DNA cleavage seen in Figures 15 and 16 
can be interpreted by a model in which both metal ion-binding sites are not filled 
simultaneously. 
 Results similar to those seen with the plasmid substrate also were observed using 
the oligonucleotide cleavage substrate described earlier. A biphasic concentration 
dependence for Ca2+-supported cleavage of the wild-type substrate and for Mn2+-
supported cleavage of the phosphorothiolate substrate are shown (Figure 17). Once again, 
these findings suggest a model that requires two simultaneously bound metal ions to 
support DNA scission mediated by E. coli topoisomerase IV. 
 As a second approach to determine the number of metal ions required to support 
the DNA cleavage reaction of bacterial type II topoisomerases, metal ion mixing 
experiments were performed (143,147,148). Initial studies utilized the wild-type 
oligonucleotide substrate and mixtures of Mg2+ and Ca2+.  This metal ion pair was used 
because Mg2+ supports DNA cleavage of the wild-type substrate poorly, even at high 
concentrations, while Ca2+ efficiently supports high levels of scission. The first time 
courses for DNA cleavage were generated in the presence of either 10 mM Mg2+, a 
saturating level, or 1 mM Ca2+, a concentration that saturates the site for metal ion A 
without appreciably filling the site for metal ion B (see Figure 17). As seen in Figure 18, 
similar low levels of cleavage were generated when either one of the metal ions was 
included in assays. However, when both metal ions were present in reactions, rates of 
cleavage increased several–fold above levels predicted from the simple arithmetic sum of 
scission observed in the presence of the individual metal ions. Furthermore, a large 
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FIGURE 17. Metal ion concentration dependence for DNA cleavage by topoisomerase IV 
with wild-type (WT) and phosphorothiolate (SPO) oligonucleotide substrates. Left, 
cleavage of a wild-type oligonucleotide in the presence of 5 µM to 20 mM Ca2+. The 
inset shows concentrations up to 2.5 mM Ca2+. Right, cleavage of an oligonucleotide 
containing a 3’-bridging phosphorothiolate in the presence of 5 µM to 10 mM Mn2+. The 
inset shows concentrations up to 0.5 mM Mn2+. All DNA cleavage reactions were 
incubated for 10 min. Error bars represent the standard deviation of three independent 
experiments. 
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FIGURE 18. Cleavage of the wild-type (WT) oligonucleotide substrate in the simultaneous 
presence of two different divalent metal ions. Time courses were carried out in the 
presence of 10 mM Mg2+ alone (green), 1 mM Ca2+ alone (red), or a mixture of 10 mM 
Mg2+ and 1 mM Ca2+ (black). The arithmetic sum of the cleavage with Mg2+ or Ca2+ alone 
is represented by the dotted line. Error bars represent the standard deviation of three 
independent experiments. 
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enhancement in the rate and level of DNA scission (compared to calculated sums) was 
observed when 10 mM Mg2+ was combined with a range of Ca2+ concentrations (0.1–1 
mM) that partially filled or saturated the high affinity metal ion site (Figure 19). 
 Even more dramatic results were observed when the oligonucleotide that 
contained a bridging phosphorothiolate was employed as the substrate. These 
experiments employed Ca2+, which supports only low levels of cleavage of the sulfur-
containing substrate, and Mn2+, which supports the highest levels of topoisomerase IV-
mediated scission of this substrate. The first experiment used 10 mM Ca2+ and 100 µM 
Mn2+, which (as above) represents the concentration that fills only metal ion site A (see 
Figure 17). As seen in Figure 20, the initial rate of cleavage was ~200–fold faster and the 
final level of cleavage increased ~20–fold in reactions that contained both metal ions as 
compared to the arithmetic sum of cleavage observed in reactions that contained only one 
of the two individual metal ions. Once again, similar results were observed in reactions 
that combined 10 mM Ca2+ and 1–100 µM Mn2+ (Figure 21). 
 In the experiments discussed above, rates and levels of DNA cleavage were 
greatly enhanced by mixing low concentrations of a metal ion that effectively fills site A 
with saturating levels (i.e., high enough to fill site B) of a second metal ion that cannot 
act effectively at site A. The most straightforward interpretation of the above findings is 
that the first (i.e., low concentration) metal ion acts primarily at site A and the second 
(i.e., saturating) metal ion acts primarily at site B. Taken together, these results argue for 
the simultaneous use of two metal ions during the DNA cleavage reaction mediated by 
bacterial topoisomerase IV and provide strong evidence for a two-metal-ion mechanism 
for DNA cleavage. 
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FIGURE 19. Topoisomerase IV-mediated cleavage of the wild-type (WT) oligonucleotide 
in the presence of different divalent metal ions. Cleavage reactions were carried out for 
0.5, 1, or 5 min in the presence of 10 mM Mg2+ alone (green bars), 100-1000 µM Ca2+ 
alone (red bars), or a mixture of 10 mM Mg2+ and 100-1000 µM Ca2+ (black bars). The 
calculated sum of cleavage in the presence of Mg2+ or Ca2+ alone is shown (stacked green 
and red bars). Error bars represent the standard deviation of three independent 
experiments. 
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FIGURE 20. Cleavage of the 3’-bridging phosphorothiolate (SPO) oligonucleotide 
substrate in the simultaneous presence of two different divalent metal ions. Time courses 
were carried out in the presence of 10 mM Ca2+ alone (red), 100 µM Mn2+ alone (blue), 
or a mixture of 10 mM Ca2+ and 100 µM Mn2+ (black). The arithmetic sum of the 
cleavage with Ca2+ or Mn2+ alone is represented by the dotted line. Error bars represent 
the standard deviation of three independent experiments. 
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FIGURE 21. Topoisomerase IV-mediated cleavage of the 3’-bridging phosphorothiolate 
(SPO) oligonucleotide in the presence of different divalent metal ions. Cleavage reactions 
were carried out for 0.5, 1, or 5 min in the presence of 10 mM Ca2+ alone (red), 1-100 µM 
Mn2+ alone (blue), or a mixture of 10 mM Ca2+ and 1-100 µM Mn2+ (black bars). The 
calculated sum of cleavage in the presence of Mg2+ or Ca2+ alone is shown (stacked red 
and blue bars). Error bars represent the standard deviation of three independent 
experiments. 
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 Although the importance of metal ion binding to sites A and B is clear, specific 
relationships between the two sites have yet to be delineated. An intriguing question is 
whether the metal ion in site B on one ParC subunit might work in concert with the metal 
ion in site A on the other ParC subunit to promote DNA scission (153). Indeed, there is 
precedent for trans cooperation between residues on opposite protomers of yeast 
topoisomerase II in the catalysis of DNA cleavage (168,169). At the present time, we 
cannot distinguish between a model in which site A and B cooperate in cis or trans. 
 Although type II topoisomerases require divalent metal ions in order to cleave the 
double helix, the role of these cations in promoting DNA scission by the bacterial type II 
enzymes has been controversial. Based on the findings discussed above, we propose that 
topoisomerase IV cleaves DNA using a two-metal-ion mechanism similar to that shown 
in Figure 9. In this model, metal ion A makes a critical interaction with the 3’-bridging 
atom of the scissile phosphate and facilitates DNA cleavage mediated by the bacterial 
type II enzyme. 
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CHAPTER IV 
 
CONTRIBUTIONS OF THE D-RING TO THE ACTIVITY OF ETOPOSIDE 
AGAINST HUMAN TOPOISOMERASE IIα: POTENTIAL INTERACTIONS WITH 
DNA IN THE TERNARY ENZYME-DRUG-DNA COMPLEX 
 
Introduction 
Etoposide is a highly successful anticancer agent that has been used to treat a 
variety of blood-borne and solid human malignancies for nearly thirty years 
(21,108,111,112). Etoposide kills cells by stabilizing covalent topoisomerase II-cleaved 
DNA complexes that are formed during the DNA strand passage reaction of the enzyme 
(22,170-172). These transient cleavage complexes are converted to permanent DNA 
strand breaks by collisions with DNA tracking systems, which generate chromosomal 
aberrations, destabilize the genome, and trigger cell death pathways. Recent evidence 
suggests that topoisomerase IIα may play a more prominent roll in mediating the 
cytotoxic effects of topoisomerase II-targeted anticancer drugs. 
 Previous studies indicate that interactions between topoisomerase II and etoposide 
are critical for drug activity and mediate the entry of etoposide into the ternary enzyme-
drug-DNA complex (119,138,139,173,174). Therefore, substituents on etoposide that 
contact topoisomerase II in the binary enzyme-drug complex have been identified by 
STD 1H NMR spectroscopy (138,139). These substituents include the C15 geminal 
protons of the A–ring, the C5 and C8 protons of the B–ring, the C2’ and C6’ protons of 
the pendant E–ring, and the 3’– and 5’–methoxyl protons of the E–ring (Figure 22). In 
contrast, no protein contacts have been observed for the C1 and C4 protons of the C-ring, 
the C2 and C3 protons that bridge the C- and D-rings, the C11 protons of the D-ring, and  
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FIGURE 22: Structures of etoposide, retroetoposide, DEPT, retroDEPT and the D-ring 
diol. 
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any protons on the C4 glycosidic moiety. An identical set of drug contacts were seen in a 
binary complex between topoisomerase IIα and DEPT, an etoposide derivative that lacks 
the C4 glycosidic group (Figure 22). 
 Protein-drug contacts in the binary complex have predictive value for the actions 
of etoposide within the ternary topoisomerase II-drug-DNA complex (138,139). Opening 
of the A-ring or altering the 3’, 4’, or 5’ substituents of the E-ring dramatically decreases 
the efficacy of etoposide, but does not affect the specificity of DNA cleavage (138,139). 
Thus, it was concluded that etoposide interacts with topoisomerase II through the A-, B-, 
and E-rings. Conversely, the loss of the C4 glycosidic group in DEPT has relatively little 
effect on the ability of the drug to enhance topoisomerase II-mediated DNA scission, but 
does induce subtle changes in cleavage specificity and site utilization (139). 
Consequently, it has been suggested that the C4 glycoside, along with the D-ring, may 
mediate interactions with DNA in the cleavage complex (139). 
 Therefore, to explore potential interactions between the D-ring and DNA during 
topoisomerase II-mediated DNA cleavage, a series of etoposide derivatives, including 
retroetoposide, retroDEPT, and the D-ring diol were characterized. Results indicate that 
D-ring alterations diminish the ability of etoposide to enhance DNA cleavage mediated 
by human topoisomerase IIα in vitro and in cultured human cells. They also decrease 
etoposide binding in the ternary enzyme-drug-DNA complex and alter sites of enzyme-
mediated DNA cleavage. Based on these findings, it is concluded that the D-ring of 
etoposide has important interactions with DNA in the topoisomerase II cleavage 
complex. 
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Results and Discussion 
Interactions between topoisomerase II and substituents on the A-ring, E-ring, and 
C4 position of etoposide in the binary enzyme-drug complex (identified by STD 1H NMR 
spectroscopy) predict the ability of etoposide to stabilize the covalent topoisomerase II-
DNA cleavage complex (138,139). However, retroetoposide and retroDEPT display 
reduced cytotoxicity (~8– and 32–fold, respectively, as compared to etoposide) against 
murine leukemia L1210 (129) despite the fact that NMR studies indicate that none of the 
protons on the D-ring of etoposide (i.e., the C2, C3 and C11 protons) contact human 
topoisomerase IIα in the binary complex (138,139). Although differences in drug 
cytotoxicity may reflect physiological attributes such as uptake or efflux, etc., this finding 
suggests that alterations in the D-ring of etoposide may affect drug activity towards 
topoisomerase IIα in the ternary enzyme-drug-DNA complex. 
 
Activity of etoposide D-ring derivatives against human topoisomerase IIα  
To address the role of the D-ring in etoposide function, the effects of 
retroetoposide, DEPT, retroDEPT, and the D-ring diol (see Figure 22 for structures) on 
DNA cleavage mediated by human topoisomerase IIα were compared to that of etoposide 
(Figure 23). As reported previously (139), the activity of DEPT was ~80-90% that of the 
parent compound. In contrast, the ability of retroetoposide, retroDEPT, and the D-ring 
diol to stimulate enzyme-mediated DNA cleavage was reduced substantially. Levels of 
DNA scission observed in the presence of retroetoposide were ~2– to 3–fold lower than 
seen with etoposide. The activity of retroDEPT was similarly reduced as compared to 
DEPT and was lower than that of retroetoposide. Thus, the effects of the two changes in  
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FIGURE 23: Effects of etoposide derivatives on DNA cleavage mediated by human 
topoisomerase IIα. Levels of double-stranded DNA cleavage were expressed as a fold–
enhancement over reactions that were carried out in the absence of drug. Assay mixtures 
contained 0–200 µM etoposide (red), DEPT (blue), retroetoposide (rEtop, outlined red), 
retroDEPT (rDEPT, outlined blue), or D-ring diol (outlined green). Error bars represent 
the standard deviation of three independent experiments. 
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etoposide to generate retroDEPT (i.e., the loss of the C4 glycoside and the transposition 
of the C13 ketone to the C11 position) appear to be additive. Finally, the D-ring diol 
displayed no ability to stimulate DNA cleavage mediated by topoisomerase IIα. 
 The above results suggest that the decreased cytotoxicity of retroetoposide and 
retroDEPT are due, at least in part, to a decreased activity against topoisomerase II. 
Together with the findings for the D-ring diol, DNA cleavage results provide strong 
evidence that substituents on the D-ring of etoposide can profoundly affect the ability of 
the drug to act as a topoisomerase II poison.  
 It has been suggested that the diminished cellular activity of retroetoposide results 
from a deleterious interaction between the C4 glycoside and the C11 carbonyl group 
(129). However, since the decreased activity of retroDEPT compared to DEPT was 
similar to that for retroetoposide compared to etoposide, this explanation seems unlikely. 
 Etoposide increases levels of cleavage complexes by inhibiting the ability of 
topoisomerase II to ligate DNA (175,176). Therefore, the effects of the D-ring derivatives 
on DNA ligation mediated by topoisomerase IIα were determined. As seen in Figure 24 
(left panel), all of the compounds displayed a reduced activity compared to etoposide, 
with the order being the same as seen in DNA cleavage assays (etoposide > DEPT > 
retroetoposide > retroDEPT >> D-ring diol). Moreover, there was a strong correlation 
between the ability of the drugs to inhibit ligation and increase levels of DNA cleavage 
(Figure 25). These results indicate that the derivatives increase levels of topoisomerase 
II-mediated strand breaks by the same mechanism as that of the parent compound (i.e., 
inhibition of DNA ligation). 
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FIGURE 24: DNA ligation was examined in the absence of compound (No Drug, black) or 
in the presence of 100 µM etoposide (red), DEPT (blue), retroetoposide (rEtop, outlined 
red), retroDEPT (rDEPT, outlined blue), or D-ring diol (outlined green). Error bars 
represent the standard deviation of three independent experiments.
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FIGURE 25: Comparison of DNA cleavage (dark yellow, 100 µM drug) and ligation (dark 
red, 30 s) mediated by human topoisomerase IIα in the presence of etoposide (E), DEPT 
(D), retroetoposide (rE), retroDEPT (rD), or D-ring diol (DRD). Error bars represent the 
standard deviation of three independent experiments. 
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 As discussed above, retroetoposide and retroDEPT are cytotoxic to leukemia 
cells, but are less potent than etoposide (129). Therefore, to determine whether the 
reduced cytotoxicity of D-ring derivatives correlates with a decreased activity against 
topoisomerase IIα, we assessed the ability of DEPT, retroetoposide, retroDEPT, and the 
D-ring diol to induce DNA cleavage by the type II enzyme in cultured human CEM 
leukemia cells. As seen in Figure 26), drug activity correlated with results of the in vitro 
DNA cleavage assays: DEPT, retroetoposide, and retroDEPT (in that order) induced 
reduced cellular levels of cleavage complexes compared to etoposide, and the D-ring diol 
displayed no activity. These findings strongly suggest that the cytotoxicity of 
retroetoposide and retroDEPT reflects drug activity against topoisomerase IIα. 
 
Interactions of etoposide D-ring derivatives with human topoisomerase IIα  
Although the C2, C3, and C11 protons associated with the D-ring of etoposide do 
not appear to interact with topoisomerase IIα in the binary complex (138,139), alterations 
in the D-ring profoundly affect the ability of the drug to poison topoisomerase IIα in vitro 
and in cultured human cells (Figures 23 and 26). This dichotomy suggests one of two 
things: either alterations in the D-ring affect contacts between etoposide and the enzyme 
in the binary complex, or this portion of etoposide has critical interactions in the ternary 
complex that are not reflected in the absence of DNA. To address these possibilities, 
interactions between topoisomerase IIα and retroetoposide, retroDEPT, and the D-ring 
diol were identified by STD 1H NMR spectroscopy.    
 Off-resonance and difference spectra for samples containing topoisomerase IIα 
and retroetoposide, retroDEPT, and the D-ring diol are shown in Figure 27. Resonances  
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FIGURE 26: Levels of topoisomerase IIα-DNA cleavage complexes formed in human 
CEM leukemia cells that were treated with etoposide derivatives. DNA samples (10 µg) 
from cultures treated with no drug (ND) or 25 µM etoposide (E), DEPT (D), 
retroetoposide (rE), retroDEPT (rD), or D-ring diol (DRD) for 1 h were blotted onto a 
nitrocellulose membrane and probed with a polyclonal antibody directed against human 
topoisomerase IIα. Error bars represent the standard deviation of three independent 
experiments. A representative blot is shown above. 
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for all visible protons for these drugs, as well as etoposide and DEPT, are given in Table 
1.  
 With the exception of one additional contact with the enzyme (the C4 proton of 
the C-ring), the substituents on retroetoposide and retroDEPT that interact with human 
topoisomerase IIα in the binary complex were the same as those previously described for 
etoposide and DEPT (138,139). However, the nuclear Overhauser enhancement (NOE) 
signals seen for the E-ring protons of both drugs were substantially broader than found 
with etoposide in the binary complex. This finding suggests that movement of the C13 
carbonyl group to the C11 position may alter the conformation around the E-ring of 
etoposide and affect interactions between this portion of the drug and the enzyme.  
 In contrast to retroetoposide and retroDEPT, the substituents on the D-ring diol 
that contact topoisomerase IIα in the binary complex were identical to those of etoposide 
and no broadening of the E-ring proton resonances were observed. This result indicates 
that the loss of the D-ring does not alter drug interactions in the binary complex and 
implies that the lack of DNA cleavage enhancement induced by this derivative results 
from a specific difference in drug interactions within the ternary complex. Therefore, a 
competition assay was carried out to address this possibility. As seen in Figure 28, the D-
ring diol was unable to displace 50 µM etoposide from the ternary topoisomerase IIα-
DNA cleavage complex, even at concentrations that were 10–fold higher than that of the 
parent compound. Thus, despite the fact that the D-ring diol and etoposide display similar 
contacts with topoisomerase IIα in the binary complex, their interactions in the ternary 
complex (at least with regard to strength) appear to differ. Because the difference 
between the binary and ternary complex is the presence of DNA, this finding suggests 
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FIGURE 28: Competition between the D-ring diol and etoposide in the ternary complex. 
Topoisomerase IIα-mediated DNA cleavage in the presence of 50 µM etoposide and 
increasing concentrations (up to 500 µM) of D-ring diol is shown as fold–enhancement 
over etoposide alone. Error bars represent the standard deviation of three independent 
experiments. 
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that the D-ring may have important interactions with the double helix in the covalent 
topoisomerase IIα-drug-DNA cleavage complex. 
 
Effects of D-ring substitutions on the specificity of topoisomerase IIα-mediated DNA 
cleavage 
A previous study demonstrated that removal of the C4 glycoside alters the 
specificity of etoposide-induced DNA cleavage by human topoisomerase IIα (also shown 
in Figure 29) (139). Based on this finding, it was proposed that the sugar moiety of 
etoposide interacts with DNA in the cleavage complex. Because the etoposide D-ring 
does not appear to contact topoisomerase IIα in the binary complex, but modification of 
this group significantly diminishes drug activity, sites of cleavage were mapped to 
determine if the D-ring also has the potential to interact with the double helix in the 
cleavage complex.  
 As seen in Figure 29, there were substantial differences in the cleavage 
specificity/site utilization of topoisomerase IIα in the presence of etoposide vs. 
retroetoposide. Similar differences were seen when comparing cleavage maps generated 
in the presence of DEPT vs. retroDEPT. In addition, opening of the D-ring (D-ring diol) 
abolished all sites of drug-induced DNA cleavage. These results indicate that the 
specificity of etoposide-induced DNA cleavage is governed, at least in part, by the D-
ring. Furthermore, results are consistent with the hypothesis that the D-ring contacts 
DNA in the topoisomerase IIα cleavage complex. Because movement of the C13 
carbonyl to the C11 position appears to affect the conformation of the etoposide E-ring, 
an alternative hypothesis is that D-ring alterations affect cleavage specificity by indirectly  
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FIGURE 29: DNA cleavage site specificity and utilization by human topoisomerase IIα in 
the presence of etoposide derivatives. A singly end-labeled linear 4332 bp fragment of 
pBR322 was used as the cleavage substrate. An autoradiogram of a polyacrylamide gel is 
shown. DNA cleavage reactions contained topoisomerase IIα with no drug (Topo), 10 
µM etoposide (Etop), 250 µM retroetoposide (rEtop), 25 µM DEPT (DEPT), 250 µM 
retroDEPT (rDEPT), or 250 µM D-ring diol (DRD). A DNA control (DNA) also is 
shown. Data are representative of four independent experiments. 
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changing protein-drug contacts. However, two findings argue against this latter 
interpretation. First, the D-ring diol displays no ability to induce topoisomerase IIα-
mediated DNA cleavage, despite the fact that the protein-drug contacts in the binary 
complex are the same as those seen with etoposide. Second, a previous study found that 
derivatization of the etoposide E-ring significantly diminishes levels of drug-induced 
DNA cleavage, but has no effect on the site specificity of human topoisomerase IIα 
(138).  
 To further examine the effects of D-ring derivatization on the cleavage specificity 
of the type II enzyme, the ability of etoposide and retroetoposide to induce topoisomerase 
IIα-mediated DNA cleavage of an oligonucleotide substrate was compared. Etoposide 
displays specificity for the -1 base relative to the scissile bond and generally prefers to 
cleave substrates with a C at this position (46,177). With the oligonucleotide used for 
cleavage experiments, etoposide preferentially induced cleavage when the substrate 
contained a -1 C or A (Figure 30). Scission levels dropped ~2–fold when a T or G was 
present at this position.  
 Compared to etoposide, retroetoposide displays a decreased specificity for a -1 C 
or A (Figure 30). In fact, levels of topoisomerase IIα-mediated DNA scission with the -1 
G substrate were comparable to those seen in the presence of C or A. This finding 
confirms that changes in the D-ring of etoposide alter the DNA cleavage specificity of the 
drug. 
 Although etoposide is in its fourth decade of clinical use, relationships between 
drug activity and interactions within the binary topoisomerase II-drug complex and the 
ternary topoisomerase II-drug-DNA complex have been addressed only recently. Based 
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FIGURE 30: Oligonucleotide sequence specificity of etoposide (red) versus retroetoposide 
(blue). Drug titrations were performed using an oligonucleotide substrate that contained a 
strong cleavage site for human topoisomerase IIα. The oligonucleotide was synthesized 
with either a C, A, T, or G at the -1 position relative to the scissile bond. The inset in the 
lower right panel compares DNA cleavage levels induced by 250 µM etoposide (red bars) 
or retroetoposide (blue bars) relative to cleavage of the oligonucleotide containing a C at 
the -1 position, which was set at 1 for both drugs. Error bars represent the standard 
deviation of three independent experiments. 
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on the results of STD 1H NMR spectroscopy and enzyme-drug binding in the binary 
complex, as well as drug competition and DNA cleavage in the ternary complex, a model 
has emerged (Figure 31). In this model, the binding of etoposide to human topoisomerase 
IIα is driven by interactions with the A–ring, B–ring, and potentially by stacking 
interactions with the E–ring (138,139). The E–ring methoxyl groups and the 4’-OH 
moiety are important for drug function, but do not contribute substantially to enzyme-
drug binding or DNA cleavage specificity (138,139).  
 Neither the C4 gylcoside nor the D-ring of etoposide contact the enzyme in the 
binary complex (138,139). While removal of the sugar has little effect on drug activity, it 
subtly alters the specificity of DNA cleavage. In contrast, D-ring modifications 
profoundly affect the ability of etoposide to induce DNA scission and alter the cleavage 
specificity of topoisomerase IIα. Taken together, we propose that interactions between 
etoposide and DNA in the ternary complex are driven primarily by the D-ring, with 
additional contributions from the C4 sugar. This hypothesis is supported by recent studies 
on F14512, an etoposide derivative that replaces the C4 glycoside with a spermine moiety 
(178-180). The presence of the spermine enhances DNA interactions and increases the 
potency of the drug against human type II topoisomerases (Figure 32) (178-180). Thus, 
by targeting the C4 moiety and the D-ring, it may be possible to develop novel etoposide 
derivatives with increased activity and/or altered cleavage specificity. 
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FIGURE 31: Summary of etoposide substituents that interact with human topoisomerase 
IIα. Protons that interact with the enzyme (as determined by STD 1H NMR spectroscopy) 
are shown in red. Interactions between hydroxyl protons and the enzyme were obscured 
by the water peak and could not be visualized. The blue region on etoposide, including 
portions of the A–, B– and E–rings, is proposed to interact with topoisomerase IIα in the 
binary drug-enzyme complex. E–ring substituents highlighted with yellow boxes are 
important for drug function and interact with the enzyme, but do not appear to contribute 
significantly to binding. We propose that interactions between etoposide and DNA in the 
ternary complex (shaded in gray) are driven primarily by the D-ring, with additional 
contributions from the C4 sugar. 
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FIGURE 32: Effects of etoposide (red) and the etoposide derivative, F14512 (blue) on 
DNA cleavage mediated by human topoisomerase IIα. Percent double-stranded DNA 
cleavage is shown. Assay mixtures contained 0–10 µM drug and 72 nM topoisomerase 
IIα. The structure of F14512 is shown above. Error bars represent the standard deviation 
of three independent experiments. 
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CHAPTER V 
 
CONCLUSIONS 
 
 Topoisomerases are enzymes that regulate DNA topology and are essential to all 
known living organisms. Cellular processes such as replication, transcription, 
recombination, as well as chromosome condensation, decondensation, and segregation 
require topoisomerases. Type II topoisomerases are targets for antibacterial and 
anticancer therapeutic drugs. 
  
Metal Ion Usage by Topoisomerase IV 
 Despite the importance of gyrase and topoisomerase IV in the regulation of DNA 
topology in bacteria and the treatment of infectious diseases, many aspects of the DNA 
cleavage reaction are poorly understood. To this point, an area of emerging interest is the 
use of divalent metal ions in catalyzing the DNA scission event. 
 The role of metal ions in the cleavage reaction mediated by bacterial type II 
enzymes has been controversial. Early evidence with gyrase indicated a two-metal-ion 
mechanism for topoisomerase type II DNA cleavage. This was subsequently supported 
by studies with the human enzyme. Recent crystallographic studies with prokaryotic type 
II enzymes have suggested that both metal ion sites might not be filled simultaneously. 
These authors proposed that type II topoisomerases might utilize a moving metal ion 
mechanism in which only one of the two metal ion sites in each protomer is filled at any 
given time.  
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 To resolve this critical issue, the DNA cleavage reaction of Escherichia coli 
topoisomerase IV was characterized. We utilized a series of divalent metal ions with 
varying thiophilicities in conjunction with oligonucleotides that replaced bridging and 
non-bridging oxygen atoms at (and near) the scissile bond with sulfur atoms. DNA 
scission was enhanced when thiophilic metal ions were used with substrates that 
contained bridging sulfur atoms. This suggests that a metal ion is making a critical 
interaction with the 3’-bridging atom of the scissile phosphate and facilitates DNA 
scission by the bacterial type II enzyme. This evidence addresses metal ion interactions 
within the cleavage complex but not the number of metal ions. 
 The metal-ion dependence of topoisomerase IV-mediated DNA cleavage is 
sigmoidal in nature. This suggests that one metal ion binds to and saturates the higher 
affinity metal binding site followed by a second metal ion binding at the lower affinity 
site. Metal ion mixing experiments further supported the simultaneous two-metal-ion 
model. 
 It is clear that biochemical studies are needed to fully understand the role of metal 
ions in type II topoisomerases. These enzymes are dynamic and difficult to crystallize. 
The addition of DNA, divalent cations, and drugs makes structural studies all the more 
difficult. While there is general agreement between biochemical and structural data on 
the positions of the metal ion binding sites, there are questions about the temporal 
occupation of these sites.  
 Ultimately, structures of type II topoisomerase-DNA complexes have been generated 
with no metal ions, one metal ion (in one of two positions), or two metal ions. Because 
structural studies only show a static enzyme in one particular conformation, in one 
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specific set of conditions, it has been difficult to generate a coherent model from 
crystallographic studies alone. 
 Understanding the interactions between DNA, enzyme, and metal ions in the active 
site of topoisomerases will lead to a greater ability to design drugs that exploit the 
dynamics of the cleavage complex. Compounds could be designed or altered to 
specifically bind DNA in the cleavage complex or take advantage of a particular cleavage 
complex intermediate. Type II topoisomerases have several moving parts and added 
variables such as DNA and metal ions impart many spatial and temporal opportunities to 
take advantage of the enzyme in the search for treatments and cures for diseases. 
 
Interactions of Etoposide with DNA in the Topoisomerase IIα Cleavage Complex 
Etoposide is has been used to treat various human malignancies for nearly thirty 
years. The drug kills cells by stabilizing covalent topoisomerase II-cleaved DNA 
complexes that are then converted to permanent DNA strand breaks by collisions with 
DNA tracking systems. These strand breaks generate chromosomal aberrations and also 
trigger apoptosis.  
Previous studies identified groups on etoposide that interact with topoisomerase 
IIα. The D-ring and C4 glycosidic moiety of etoposide did not interact with the enzyme 
in the binary enzyme-drug complex. To explore potential interactions between the D-ring 
and DNA during topoisomerase II-mediated DNA cleavage, a series of etoposide 
derivatives, including retroetoposide, retroDEPT, and the D-ring diol were characterized.  
D-ring alterations diminish the ability of etoposide to enhance DNA cleavage 
mediated by human topoisomerase IIα in vitro and in cultured human cells. This shows 
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that, while the D-ring does not appear to be interacting with topoisomerase IIα in the 
binary complex, it is important for drug activity. Changes in the D-ring also decrease 
etoposide binding in the ternary enzyme-drug-DNA complex and alter sites of enzyme-
mediated DNA cleavage. Based on these findings, it is concluded that the D-ring of 
etoposide has important interactions with DNA in the topoisomerase II cleavage 
complex. 
To date, there are no topoisomerase II crystal structures that contain etoposide or 
any other anticancer drug. It is therefore not precisely known how etoposide interacts 
with the topoisomerase II cleavage complex. Understanding the orientation, position, and 
important substituents of etoposide in the cleavage complex could lead to the design of 
drugs with greater efficacy and possibly more specificity. Recent studies that increase 
drug-DNA interactions by replacing the C-4 glycoside of etoposide with a spermine 
moiety show that greater understanding of the importance and interactions of etoposide 
substituents can lead to more efficacious drugs. 
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